

Pertussis vaccine – pregnant women are the target group in the childhood vaccination programme

FROM THE SPECIALTIES

HILDE MARIE ENGJOM

hildemarie.engjom@fhi.no

Hilde Marie Engjom, PhD, specialist in obstetrics and gynaecology, and senior medical officer in the Department for Health Registry Research and Development, Norwegian Institute of Public Health.

The author has completed the ICMJE form and declares no conflicts of interest.

FREDRIK SKÅR

Fredrik Skår, medical doctor at the Section for Respiratory, Bloodborne and Sexually Transmitted Infections, Norwegian Institute of Public Health.

The author has completed the ICMJE form and declares no conflicts of interest.

HINTA MEIJERINK

Hinta Meijerink, PhD, senior adviser in the Department of Infection Control and Vaccines, Norwegian Institute of Public Health.

The author has completed the ICMJE form and declares no conflicts of interest.

INGER JOHANNE LANDSJØÅSEN BAKKEN

Inger Johanne Landsjøåsen Bakken, DEng, senior adviser in the Department of Data Management and Quality, Norwegian Institute of Public Health and in the Norwegian Patient Registry.

The author has completed the ICMJE form and declares no conflicts of interest.

GURI SUNDGOT HALVORSEN

Guri Sundgot Halvorsen, civil engineer in physics and mathematics. Senior adviser in the Department of Health Registries, Norwegian Institute of Public Health.

The author has completed the ICMJE form and declares no conflicts of interest.


EVY THERESE DVERGSDAL

Evy Therese Dvergsdal, MSc Public Health. Senior adviser in the Department of Infection Control and Vaccines, Norwegian Institute of Public Health. The author has completed the ICMJE form and declares no conflicts of interest.

MARGRETHE GREVE-ISDAHL

Margrethe Greve-Isdahl, specialist in paediatrics and senior medical officer in the Department of Infection Control and Vaccines, Norwegian Institute of Public Health. She is head of the childhood vaccination programme. The author has completed the ICMJE form and declares no conflicts of interest.

The Norwegian Parliament has passed a resolution to introduce maternal pertussis vaccination to protect infants. As part of the implementation, the Norwegian Institute of Public Health is planning important improvements in the monitoring of maternal vaccination.



Bordetella pertussis, the bacterium that causes pertussis. Scanning electron microscopy shows the bacterium (green) in the respiratory epithelium of the trachea. Illustrative photo: Science Photo Library/NTB

Infants are particularly vulnerable to respiratory infection with *Bordetella pertussis*, which causes whooping cough. Severe illness with respiratory arrest may be the first symptom. The most common complications of pertussis are breathing difficulties, nutritional problems and secondary infections. Encephalopathy and death are rare.

The pertussis vaccine was incorporated into the childhood vaccination programme in 1952, with the first vaccine dose given at three months of age [\(1\)](#). Neither vaccination nor previous illness provide permanent immunity. The bacterium is circulating in the population, and following reduced transmission during the COVID-19 pandemic, several European countries are now reporting an increase in transmission, severe illness and death in infants [\(2, 3\)](#).

Neonates have an immature immune system and poor response to vaccines [\(4\)](#). When a woman is vaccinated during pregnancy, her antibodies are transferred to the fetus, providing protection for the infant until they can be vaccinated [\(5, 6\)](#).

Maternal pertussis vaccination has been introduced in a number of countries, including the Nordic region. The Norwegian Parliament passed a resolution to incorporate maternal vaccination into the primary care childhood vaccination programme in the 2024 national budget. The Norwegian Institute of Public Health recommends that the combination vaccine Boostrix (pertussis/tetanus/diphtheria) be given at the routine check-up in week 24 in every pregnancy. Common adverse effects for pregnant women are pain at the injection site, fever, mild fatigue and feeling unwell for a few days. Follow-up studies have not shown adverse effects in the child. Women who are more than 24 weeks pregnant when the programme starts in May 2024 should also be offered the vaccine.

Facilitation by the primary healthcare service is crucial to ensure that all pregnant women are reached, and general practitioners, public health nurses and midwives should all be enabled to administer the vaccine. In close collaboration with healthcare professionals, we have devised an online training course for all healthcare personnel groups (7).

Pregnant women are a new target group for pertussis vaccination in the childhood vaccination programme, and we are working with the Norwegian Medical Products Agency on extended monitoring of adverse effects in the first year. This is standard practice when introducing vaccines to new population groups and is important for the follow-up in Norway.

The new procedures for improved monitoring of infection and vaccination in mothers and children are based on experiences from the introduction of new vaccines and surveillance during the COVID-19 pandemic. The work involves linking and analysing data from the Norwegian Surveillance System for Communicable Diseases (MSIS), the Norwegian Immunisation Registry (SYSVAK), the Norwegian Patient Registry (NPR) and the Medical Birth Registry of Norway. Since 1 January 2024, these national health registers have been assembled at the Norwegian Institute of Public Health. This collaboration between the experts from the registries will also improve monitoring of infection and vaccination for other diseases in pregnant women and children, such as COVID-19 and influenza, and strengthen the preparedness for future outbreaks or pandemics.

REFERENCES

1. Riise OR, Laake I, Vestrheim D et al. Risk of Pertussis in Relation to Degree of Prematurity in Children Less Than 2 Years of Age. *Pediatr Infect Dis J* 2017; 36: e151–6. [PubMed][CrossRef]
2. Folkehelseinstituttet. Framtidens utfordringer for folkehelsen. <https://www.fhi.no/he/fremtidens-utfordringer-for-folkehelsen/?term=> Accessed 22.4.2024.
3. European Centre for Disease Prevention and Control. Communicable Disease Threats Report. <https://www.ecdc.europa.eu/en/publications-and-data/monitoring/weekly-threats-reports> Accessed 24.4.2024.
4. Halasa NB, O'Shea A, Shi JR et al. Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. *J Pediatr* 2008; 153: 327–32.

[PubMed][CrossRef]

5. Amirthalingam G, Andrews N, Campbell H et al. Effectiveness of maternal pertussis vaccination in England: an observational study. *Lancet* 2014; 384: 1521–8.

[PubMed][CrossRef]

6. Maertens K, Tran TMP, Hens N et al. Effect of Prepregnancy Pertussis Vaccination in Young Infants. *J Infect Dis* 2017; 215: 1855–61. [PubMed][CrossRef]

7. Folkehelseinstituttet. Kikhostevaksine til gravide – undervisning for helsepersonell. <https://vimeo.com/933288628> Accessed 22.4.2024.

Publisert: 29 May 2024. Tidsskr Nor Legeforen. DOI: 10.4045/tidsskr.24.0208

Received 13.4.2024, first revision submitted 22.4.2024, accepted 24.4.2024.

Copyright: © Tidsskriftet 2026 Downloaded from tidsskriftet.no 13 July 2026.